Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-02-01 Epub Date: 2024-03-14 DOI:10.1080/07357907.2024.2330102

Fatih Gürler, Selin Aktürk Esen, Bediz Kurt İnci, Osman Sütçüoğlu, Gökhan Uçar, Orhun Akdoğan, Doğan Uncu, Nesrin Turhan, Nalan Akyürek, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı

引用次数: 0

Abstract

We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor. A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.

查看原文本刊更多论文

胃肠胰神经内分泌肿瘤中 PD-L1、LAG-3、TIM-3、OX40L 表达和 MSI 状态的回顾性分析

我们调查了作为免疫检查点蛋白的 PD-L1、LAG-3、TIM-3 和 OX40L 的表达情况，并通过组织块的免疫组化分析了 MSI（DNA 修复系统缺陷导致的重复短 DNA 序列）状态。在 83 例患者中，18.1% 的患者（n = 15）有 PD-L1 表达。没有患者出现 LAG-3 表达。TIM-3表达率为4.9%（n = 4），OX40L表达率为22.9%（n = 19），8.4%（n = 7）的患者患有MSI肿瘤。PD-L1和TIM-3的表达呈中低度正相关（rho：0.333, p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.